VRDN
Viridian Therapeutics Inc
NASDAQ: VRDN · HEALTHCARE · BIOTECHNOLOGY
$13.48
+1.35% today
Updated 2026-04-30
Market cap
$1.37B
P/E ratio
—
P/S ratio
19.35x
EPS (TTM)
$-3.32
Dividend yield
—
52W range
$12 – $34
Volume
2.3M
Viridian Therapeutics Inc (VRDN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.78M | $3.67M | $8.09M | $12.90M | $4.26M | $52.48M | $66.15M | $30.26M | $131.25M | $203.71M | $435.09M | $490.42M | $742.40M |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | $1.66M | $2.05M | $6.79M | $11.73M | $4.26M | $51.87M | $65.37M | $29.74M | $129.61M | $200.16M | $424.55M | $486.48M | $738.46M |
| Total liabilities | $24.22M | $1.65M | $2.10M | $2.49M | $4.58M | $13.97M | $14.80M | $14.51M | $11.22M | $15.99M | $40.03M | $48.40M | $70.76M |
| Current liabilities | $23.60M | $1.39M | $1.99M | $2.47M | $4.58M | $3.90M | $6.73M | $10.18M | $10.67M | $13.64M | $33.35M | $26.64M | $47.87M |
| Long-term debt | — | — | — | — | — | $9.92M | $8.00M | $4.33M | — | — | $4.64M | $20.20M | $20.58M |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | $-21.44M | $-25.89M | $-6.64M | $-17.97M | $-30.64M | $-93.59M | $-126.30M | $-168.17M | $-278.89M | $-358.30M | $-488.17M | $-725.91M | $-995.86M |
| Accounts receivable | $1.20M | $994010.00 | $1.09M | $394000.00 | $524000.00 | $1.46M | $24000.00 | $108000.00 | — | $451000.00 | $102000.00 | $102000.00 | — |
| Inventory | $169539.00 | $356641.00 | $179000.00 | $187000.00 | $64000.00 | $1.00 | — | — | — | — | $-6.62M | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | — |